CDC: Age Range Expanded for Meningococcal Vaccine

Report reveals that two licensed meningococcal conjugate vaccines likely interchangeable

THURSDAY, Aug. 4 (HealthDay News) -- MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, appears to be safe and effective for use with the recently extended age indication, and is interchangeable with the other licensed meningococcal conjugate vaccine, MenACWY-D (Menactra, Sanofi Pasteur), according to a report in the Aug. 5 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

The Food and Drug Administration lowered the approval age range for use of MenACWY-CRM to include individuals aged 2 through 55 years. Another quadrivalent meningococcal conjugate vaccine, MenACWY-D, is approved in the United States for prevention of meningococcal disease caused by serogroups A, C, Y, and W-135 among those aged 2 through 55 years. MenACWY-D is also approved as a two-dose series among children aged 9 to 23 months.

The Advisory Committee on Immunization Practices (ACIP) recommends that individuals aged 2 to 55 years, at an elevated risk for meningococcal disease, and all adolescents aged 11 to 18 years be immunized with meningococcal conjugate vaccine. In addition, the ACIP recommends that all adolescents receive a booster dose of quadrivalent meningococcal conjugate vaccine at 16 years of age.

"At this time, no data exist on the use of MenACWY-D following primary vaccination with MenACWY-CRM," the authors write. "Health care providers should use every opportunity to provide the booster dose when indicated, regardless of the vaccine brand used for the previous dose or doses."

Full Text

Physician's Briefing